Understanding how transposons are inhibited during male fetal gonad development
Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans
This study is trying to understand how certain genetic elements are kept in check during the development of male fetal testicles by looking at tissue samples from male fetuses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 10 Weeks to 37 Weeks |
| Sex | Male |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Trial ID | NCT02171845 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the mechanisms and factors that inhibit transposons during the development of male fetal gonads. It will include 30 patients over a period of 36 months, focusing on male fetuses at various gestational ages who are undergoing medical or voluntary termination of pregnancy. Tissue samples, primarily gonads along with liver and psoas muscle for control, will be collected and analyzed using molecular biology techniques to quantify transposon expression and their inhibitors.
Who should consider this trial
Good fit: Ideal candidates for this study are couples or mothers who have provided informed consent for male fetuses between 10 and 37 weeks of gestation undergoing medical or voluntary termination of pregnancy.
Not a fit: Patients whose fetuses have aneuploidy or malformations of the genital organs will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of fetal development and transposon regulation, potentially informing future reproductive health strategies.
How similar studies have performed: While the specific focus on transposon inhibition during fetal gonad development is novel, similar studies exploring transposon activity in other contexts have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Couple or mother who has provided written informed consent * Foetus between 10 and 37 weeks of amenorrhea (WA) * Male foetus * Foetus obtained following medical termination of pregnancy or voluntary termination of pregnancy Exclusion Criteria: * persons without national health insurance cover * foetus presenting aneuploidy * foetus presenting a malformation of the genital organs
Where this trial is running
Dijon
- CHU de DIJON — Dijon, France (Recruiting)
Study contacts
- Study coordinator: Patricia FAUQUE
- Email: patricia.fauque@chu-dijon.fr
- Phone: 3.80.29.50.31
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.